⌘K
Sahajanand Medical Technologies is a prominent medical device company specializing in cardiovascular devices such as Drug-Eluting Stents (DES), PTCA balloons, TAVI systems, and Occluders. The company emphasizes strong clinical evidence, continuous product innovation, and a global presence across 70+ countries.
The company exhibits strong business quality, consistent revenue and profit growth, and operates in a favorable industry. However, these positives are significantly overshadowed by an expensive valuation (P/E 57.91x vs. peer average 43.87x) and extremely weak market sentiment, evidenced by an overall IPO subscription of only 0.35x. Additionally, governance concerns such as outstanding litigation, past regulatory non-compliance, and a relatively low post-IPO promoter holding add to the risk profile. While anchor investor participation provides some comfort, the lack of broader investor demand at this valuation makes it a risky proposition for listing gains and short-term investment.
Despite a historical GMP peak, the extremely poor overall subscription (0.35x) and high valuation make significant listing gains highly unlikely and risky. A listing at a discount or flat is more probable.
The combination of high valuation, weak market sentiment (undersubscription), and identified governance/operational risks suggests poor short-term performance. Capital preservation is paramount.
While the company operates in a growing industry and has a strong business model with good growth strategies, the current valuation and governance concerns warrant caution. Long-term potential exists if valuation corrects and risks are mitigated, but it's not a compelling 'Apply' at this price.
Listing-day performance is not available yet. It will appear here once this IPO has listed and results are recorded.
| Category | Shares Offered | % of Issue | Share |
|---|---|---|---|
| QIB | 67,86,058 | 49.1% | |
| NII (HNI) | 20,35,817 | 14.73% | |
| Retail | 47,50,241 | 34.37% | |
| Employee | 2,50,000 | 1.81% |
| Investor | |||
|---|---|---|---|
| NIPPON INDIA SMALL CAP FUND | 11,45,090 | ₹39.39 Cr | 28.12% |
| DSP HEALTHCARE FUND | 5,90,992 | ₹20.33 Cr | 14.51% |
| WHITEOAK CAPITAL FLEXI CAP FUND | 1,84,341 | ₹6.34 Cr | 4.53% |
| WHITEOAK CAPITAL MULTI ASSET ALLOCATION FUND | 87,204 | ₹3 Cr | 2.14% |
| WHITEOAK CAPITAL PHARMA & HEALTHCARE FUND | 1,45,340 | ₹5 Cr | 3.57% |
| INVESCO INDIA PHARMA & HEALTHCARE FUND | 4,36,063 | ₹15 Cr | 10.71% |
| UTI HEALTHCARE FUND | 4,36,063 | ₹15 Cr | 10.71% |
| ALLIANZ GLOBAL INVESTORS FUND-ALLIANZ INDIA EQUITY | 4,36,063 | ₹15 Cr | 10.71% |
| TATA AIA LIFE INSURANCE CO.LTD.-WHOLE LIFE AGGRESSIVE GROWTH FUND-ULIF 010 04/01/07 WLA 110 | 2,90,723 | ₹10 Cr | 7.14% |
| NATIXIS INTERNATIONAL FUNDS (LUX) I-LOOMIS SAYLES GLOBAL EMERGING MARKETS EQUITY FUND | 3,19,755 | ₹11 Cr | 7.85% |
Grey-market premium history is not yet available for this issue.
Consistent revenue and strong PAT growth over the last two fiscal years.
Improving EBITDA and PAT margins.
Low debt-to-equity ratio, indicating financial stability.
Strong and diversified product portfolio in the high-growth cardiovascular medical device segment.
Significant global presence and clear strategies for market expansion and product innovation.
Operating in a growing medical device industry with favorable tailwinds.
Participation of quality anchor investors, providing some institutional backing.
Successful launch of next-generation products (e.g., Hydra TAVI), deeper penetration in existing and new international markets, strategic acquisitions, and sustained industry growth.
Steady growth in existing product lines, moderate market expansion, and stable regulatory environment. Continued improvement in operational efficiencies.
Intensified competition, adverse regulatory changes, product recalls, failure to retain key personnel, or prolonged negative operating cash flows.
Positive: Consistent revenue and strong PAT growth (FY24-FY26).
Concern: High valuation (P/E 57.91x) compared to peers and industry average.
Advisory: reported profit not backed by operating cash flow (paper-profit risk)
Listing-gain vs long-term: Avoid / Neutral.